Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of "Buy" by Brokerages

Annexon, Inc. (NASDAQ:ANNX - Get Free Report) has been assigned an average recommendation of "Buy" from the six research firms that are currently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $15.80.

Several research analysts recently commented on ANNX shares. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Annexon in a research note on Tuesday, December 17th. Needham & Company LLC reissued a "buy" rating and set a $16.00 price objective on shares of Annexon in a research report on Friday, November 15th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Annexon in a report on Friday, November 15th.

Annexon Stock Performance

Shares of NASDAQ:ANNX traded down $0.02 during trading on Wednesday, hitting $4.15. The company's stock had a trading volume of 1,241,477 shares, compared to its average volume of 1,507,032. Annexon has a fifty-two week low of $3.86 and a fifty-two week high of $8.40. The business has a 50 day moving average price of $5.03 and a two-hundred day moving average price of $5.91. The company has a market capitalization of $442.35 million, a PE ratio of -3.95 and a beta of 1.11.

Institutional Investors Weigh In On Annexon

Institutional investors have recently added to or reduced their stakes in the business. Sandia Investment Management LP acquired a new stake in shares of Annexon during the second quarter worth about $49,000. Victory Capital Management Inc. purchased a new position in Annexon during the 2nd quarter worth approximately $51,000. Quarry LP acquired a new position in Annexon during the third quarter worth approximately $118,000. Intech Investment Management LLC purchased a new stake in Annexon in the third quarter valued at approximately $154,000. Finally, Maven Securities LTD purchased a new stake in Annexon in the second quarter valued at approximately $170,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.